denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Biological therapies, Non-Biological therapies, Lymphomas, B Cell lymphoma, Diseases, Therapies, aggressive lymphoma, Lymphoid Malignancies
Description:
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy worldwide comprising approximately 30% of all lymphomas. Currently, 50-60% of patients diagnosed with DLBCL are alive at 5 years and cured with modern therapy, but approximately 10-15% of patients will be refractory to first-line therapy and an additional 20-30% will relapse following a complete response. For the majority of patients who relapse, this occurs within the first 2 years of initial therapy. Patients who experience early relapse or who have primary refractory disease (less than a complete response or relapse within 3 to 6 months to initial therapy) have poor outcomes.
Dr Kate Cwynarski will outline the recent evidence questioning the efficacy of traditional methods for delivering CNS prophylaxis and the increasing focus on alternative interventions for this important clinical problem. She will also discuss the currently available risk stratification models and methods for identifying patients at high risk of CNS relapse and the potential for novel molecular diagnostics to improve patient selection in the future. She will also outline novel and emerging therapies presently under investigation. The talk will propose a revised approach to this contentious issue.
Dr. Christopher Flowers will use patient scenarios to illustrate some of the key challenges faced by patients with relapsed DLBCL. He will discuss conventional management strategies for patients with relapsed/refractory DLBCL including high dose therapy and autologous stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy. He will also discuss results of recent trials that may change standard approaches and provide algorithms for sequencing therapy and managing patients in the modern era.
Dr. Anita Kumar will discuss the current guidelines and existing data that support the use of upfront autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL). In contrast, she will also present the emerging evidence that challenges the applicability of this approach in the modern era. Additionally, she will discuss risk factors associated with outcome after ASCT and the potential role of minimal residual disease assessment in refining patient selection for ASCT in the future. Finally, she will discuss novel treatment approaches that incorporate biologically targeted therapies and risk-adapted treatment paradigms that are actively under investigation. Using a case-based approach, Dr. Kumar will highlight future opportunities for changing the established treatment paradigm for “transplant-eligible” MCL patients.
Dr Kate Cwynarski will outline the recent evidence questioning the efficacy of traditional methods for delivering CNS prophylaxis and the increasing focus on alternative interventions for this important clinical problem. She will also discuss the currently available risk stratification models and methods for identifying patients at high risk of CNS relapse and the potential for novel molecular diagnostics to improve patient selection in the future. She will also outline novel and emerging therapies presently under investigation. The talk will propose a revised approach to this contentious issue.
Dr. Christopher Flowers will use patient scenarios to illustrate some of the key challenges faced by patients with relapsed DLBCL. He will discuss conventional management strategies for patients with relapsed/refractory DLBCL including high dose therapy and autologous stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy. He will also discuss results of recent trials that may change standard approaches and provide algorithms for sequencing therapy and managing patients in the modern era.
Dr. Anita Kumar will discuss the current guidelines and existing data that support the use of upfront autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL). In contrast, she will also present the emerging evidence that challenges the applicability of this approach in the modern era. Additionally, she will discuss risk factors associated with outcome after ASCT and the potential role of minimal residual disease assessment in refining patient selection for ASCT in the future. Finally, she will discuss novel treatment approaches that incorporate biologically targeted therapies and risk-adapted treatment paradigms that are actively under investigation. Using a case-based approach, Dr. Kumar will highlight future opportunities for changing the established treatment paradigm for “transplant-eligible” MCL patients.